Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,974 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor.
Dotsu Y, Yamaguchi H, Fukuda M, Suyama T, Honda N, Umeyama Y, Taniguchi H, Gyotoku H, Takemoto S, Tagawa R, Ogata R, Tomono H, Shimada M, Senju H, Nakatomi K, Nagashima S, Soda H, Ikeda H, Ashizawa K, Mukae H. Dotsu Y, et al. Among authors: taniguchi h. J Clin Med. 2021 Sep 17;10(18):4221. doi: 10.3390/jcm10184221. J Clin Med. 2021. PMID: 34575334 Free PMC article.
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T, Fukuda M, Nakamura Y, Kinoshita A, Senju H, Nakano H, Kitazaki T, Ogawara D, Taniguchi H, Motoshima K, Yamaguchi H, Nakatomi K, Shimada M, Nagashima S, Tsukamoto K, Kohno S; Nagasaki Thoracic Oncology Group. Ikeda T, et al. Among authors: taniguchi h. Cancer Chemother Pharmacol. 2014 Sep;74(3):497-502. doi: 10.1007/s00280-014-2527-4. Epub 2014 Jul 18. Cancer Chemother Pharmacol. 2014. PMID: 25034978 Free article. Clinical Trial.
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. Taniguchi H, et al. Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0. Nat Commun. 2019. PMID: 30651547 Free PMC article.
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer.
Taniguchi H, Yamaguchi H, Dotsu Y, Shimada M, Gyotoku H, Senju H, Takemoto S, Kitazaki T, Fukuda M, Ogawara D, Soda H, Nakatomi K, Sugasaki N, Kinoshita A, Nagashima S, Ikeda T, Nakamura Y, Sakamoto N, Obase Y, Fukuda M, Mukae H. Taniguchi H, et al. Thorac Cancer. 2019 Sep;10(9):1764-1769. doi: 10.1111/1759-7714.13134. Epub 2019 Jul 16. Thorac Cancer. 2019. PMID: 31309738 Free PMC article. Clinical Trial.
Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
Shimada M, Yamaguchi H, Fukuda M, Tomono H, Honda N, Dotsu Y, Taniguchi H, Gyotoku H, Senju H, Takemoto S, Ikeda T, Nakatomi K, Nakamura Y, Nagashima S, Yamazaki T, Mukae H. Shimada M, et al. Among authors: taniguchi h. Cancer Chemother Pharmacol. 2019 Nov;84(5):1059-1064. doi: 10.1007/s00280-019-03940-0. Epub 2019 Sep 5. Cancer Chemother Pharmacol. 2019. PMID: 31486872 Clinical Trial.
2,974 results